BioCentury
ARTICLE | Clinical News

Banzel rufinamide regulatory update

March 16, 2015 7:00 AM UTC

FDA approved an sNDA from Eisai for Banzel rufinamide as an adjunct treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ages 1-4. Eisai markets the triazole derivative in the U.S. as Banzel and in the EU as Inovelon as adjunctive treatment of seizures associated with LGS in patients ages >=4 years. ...